Taro Pharmaceutical Industries Ltd reports results for the quarter ended in September - Earnings Summary

Taro Pharmaceutical Industries

28/10/2022 11:16

* Taro Pharmaceutical Industries Ltd  TARO.N  reported a
quarterly
adjusted loss of 7 cents​​ per share for the quarter ended in
September. The lone analyst forecast for the quarter was
for earnings of 84 cents per share.
    * Revenue fell 1.1% to $130.50 million from a year ago;
analysts
expected $161.02 million. 
    * Taro Pharmaceutical Industries Ltd's reported EPS for the
quarter was a loss of 7 cents​.
    * The mean earnings estimate of analysts had fallen by
about 10.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Taro Pharmaceutical Industries Ltd shares had risen
by 10.0%
this quarter and lost 34.2% so far this year.
    * The company reported a quarterly loss of $2.81 million.
    * Wall Street's median 12-month price target for Taro
Pharmaceutical Industries Ltd is $54.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data October
28 at 10:16 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      0.84           -0.07          Missed
 Jun. 30 2022      0.85           0.37           Missed
 Mar. 31 2022      0.88           0.73           Missed
 Dec. 31 2021      0.91           0.70           Missed